Cost-effectiveness of hepatitis B vaccination in haemodialysis patients

South African Medical Journal

Volumn 91, Issue 4, 2001, Pages 340-344

  Taal, M W ^a   Van Zyl Smit, R ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DELTOID MUSCLE; FEMALE; HEMODIALYSIS PATIENT; HEPATITIS B; HUMAN; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PREVALENCE; SEROCONVERSION; SOUTH AFRICA; VACCINATION; VIRUS CARRIER;

ADULT; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; SOUTH AFRICA;

EID: 0035012202     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. London WT, Drew JS, Lustbader ED, Werner BG, Blumberg BS. Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 1977; 12: 51-58.
2. Szmuness W, Prince AM, Grady GF, et al. Hepatitis B infection. A point-prevalence study in 15 US hemodialysis centres. JAMA 1974; 227: 901-906.
3. Dueymes JM, Bodenes-Dueymes M, Mahe JL, Herman B. Detection of hepatitis B viral DNA by polymerase chain reaction in dialysis patients. Kidney Int Suppl 1993; 41: S161-166.
4. Josselson J, Kyser BA, Weir MR, Sadler JH. Hepatitis B surface antigenemia in a chronic hemodialysis program; lack of influence on morbidity and mortality. Am J Kidney Dis 1987; 9: 4556-461.
5. Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis 1988; 11: 210-213.
6. Miller DJ, Williams AE, Le Bouvier GL, Dwyer JM, Grant J, Klatskin G. Hepatitis B in hemodialysis patients: significance of HBeAg. Gastroenterology 1978; 74: 1208-1213.
7. Parfrey PS, Forbes RD, Hutchinson TA, et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 1985; 39: 610-615.
8. Polakoff S, Cossart YE, Tillett HE. Hepatitis in dialysis units in the United Kingdom. BMJ 1972; 3: 94-99.
9. Garibaldi RA, Forrest JN, Bryan JA, Hanson BF, Dismukes WE. Hemodialysis-associated hepatitis. JAMA 1973; 225: 384-389.
10. Polakoff S, Tillett HE. Decrease in the incidence of hepatitis in dialysis units associated with prevention programme. BMJ 1974; 4: 751-754.
11. Najem GR, Louria DB, Thind IS, et al. Control of hepatitis B infection. The role of surveillance and an isolation hemodialysis center. JAMA 1981; 245: 153-157.
12. Desmyter J, Colaert J, De Groote G, et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983; 2: 1323-1328.
13. Crosnier J, Jungers P, Courouce AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet 1981; 1: 455-459.
14. Jilg W, Schmidt M, Weinel B, et al. Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. J Hepatol 1986; 3: 190-195.
15. Lelie PN, Reesink HW, de Jong-van Manen ST, Dees PJ, Reerink-Brongers EE. Immunogenicity and safety of a plasma-derived heat-inactivated hepatitis B vaccine (CLB). Studies in volunteers at a low risk of infection with hepatitis B virus. Am J Epidemiol 1934; 120: 694-702.
16. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984; 311: 496-501.
17. Bruguera M, Cremades M, Mayor A, Sanchez Tapias JM, Rodes J. Immunogenicity of a recombinant hepatitis B vaccine in haemodialysis patients. Postgrad Med J 1987; 2: 155-158.
18. Kohler H, Arnold W, Renschin G, Dormeyer HH, Meyer zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124-128.
19. Crosnier J, Jungers P, Courouce AM, et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet 1981; 1: 797-800.
20. Benhamou E, Courouce AM, Jungers P, et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 1984; 21: 143-147.
21. Lelie PN, Reesink HW, de Jong-van Manen ST, Dees PJ, Reerink-Brongers EE. Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med 1985; 145: 305-309.
22. Bruguera M, Cremades M, Rodicio JL, et al. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med 1989; 87:30S-32S.
23. Guan R, Tay HH, Choong HL, Yap I, Woo KT. Hepatitis B vaccination in chronic renal failure patients undergoing haemodialysis: the immunogenicity of an increased dose of a recombinant DN A hepatitis B vaccine. Ann Acad Med Singapore 1990; 19: 793-797.
24. Hadler SC, Francis DP, Maynard JE, et al Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986; 315: 209-214.
25. Eddleston A. Modern vaccines. Hepatitis. Lancet 1990; 335: 1142-1145.
26. Schoub BD. Estimations of the total size of the HIV and hepatitis B epidemics in South Africa. S Afr Med J 1992; 81: 63-66.
27. Tucker TJ, Kirsch RE, Louw SJ, Isaacs S, Kannemeyer J, Robson SC. Hepatitis E in South Africa: evidence for sporadic spread and increased seroprevalence in rural areas. J Med Virol 1996; 50: 117-119.